

A2 P20953.A01

(C<sub>1-4</sub>)alkyldextran polyalcohol.

Sub D36  
A3  
11. (Amended - Clean Copy) The DDS compound according to claim 9, which is obtainable by modifying with a saccharide compound a carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol produced by binding a residue of drug compound to a part of carboxyl groups of the carboxy (C<sub>1-4</sub>)alkyl moiety of the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol by means of a spacer comprising one amino acid or a spacer comprising 2 to 8 amino acids linked by peptide bond(s).

12. (Amended - Clean Copy) The DDS compounds according to claim 1, wherein the saccharide compound is galactose or galactosamine, or a derivative thereof.

13. (Amended - Clean Copy) The DDS compounds according to claim 1, wherein the saccharide compound is N-acetylgalactosamine.

Sub D37  
A4  
14. (Amended - Clean Copy) The DDS compounds according to claim 1, wherein the dextran polyalcohol that constitutes the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol is a dextran polyalcohol which is obtained by treating dextran under conditions that enable substantially complete polyalcoholization.

15. (Amended - Clean Copy) The DDS compound according to claim 1, wherein the carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol is carboxymethyldextran polyalcohol.

16. (Amended - Clean Copy) The DDS compound according to claim 1, wherein the drug compound is an antineoplastic agent or an anti-inflammatory agent.

Sub D40  
A5  
17. (Amended - Clean Copy) The DDS compound according to claim 1, wherein the drug compound is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione.

A6 21. (Amended - Clean Copy) A carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol for use in the manufacture of the DDS compound according to claim 1.

A7 27. (Amended - Clean Copy) The method according to claim 24, wherein the hydrolysate is the drug compound.

28. (Amended - Clean Copy) The method according to claim 24, wherein the hydrolysate is a compound comprising the residue of drug compound bound with a part of the spacer.

A8 29. (Amended - Clean Copy) The method according to claim 24, wherein the polymer carrier is a polysaccharide derivative having carboxyl groups.

30. (Amended - Clean Copy) The method according to claim 24, wherein the drug compound introduced to the DDS compound is an antineoplastic agent or an anti-inflammatory agent.

A9 31. (Amended - Clean Copy) The method according to claim 24, wherein the spacer is a tetrapeptide represented by -Gly-Gly-Phe-Gly- from the N-terminal or a tetrapeptide represented by -Gly-Gly-Gly-Phe- from the N-terminal.

32. (Amended - Clean Copy) The method according to claim 24, wherein the spacer is a group represented by -Gly-Gly-Phe-Gly-HN-Y'-CH<sub>2</sub>-O-CO- from the N-terminal or a group represented by -Gly-Gly-Gly-Phe-NH-Y'-CH<sub>2</sub>-O-CO- from the N-terminal wherein Y' represents p-phenylene group.

33. (Amended - Clean Copy) The method according to claim 24, wherein the peptidase is  $\alpha$ -chymotrypsin or papain.

P20953.A01

36. (Amended - Clean Copy) The method according to claim 24, wherein the drug compound is (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione.

37. (Amended - Clean Copy) The method according to claim 24, which is used for measurement of a DDS compound in which a carboxy(C<sub>1-4</sub>)alkyldextran polyalcohol and (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione are bound to each other by means of a spacer comprising a tetrapeptide represented by -Gly-Gly-Phe-Gly- or a tetrapeptide represented by -Gly-Gly-Gly-Phe- from the N-terminal.

REMARKS

Entry of this amendment is respectfully requested prior to examination of the application and calculation of filing fees. In particular, this amendment is being made to remove multiple dependent claims and the government fees associated therewith.

Should the Examiner have any further comments or questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully submitted,  
Hiroshi SUZAKI et al.

Arnold Turk  
Reg. No. 33,094

April 27, 2001  
GREENBLUM & BERNSTEIN, P.L.C.  
1941 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191